Aprus Bio-Medical Innovations Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.85 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2020
About Aprus Bio-Medical Innovations
Aprus Bio-Medical Innovations Private Limited (ABIPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 09 March 2016 (Eight years and 11 months 2 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.85 M, as per Ministry of Corporate Affairs (MCA) records.
Anand Iyer, Ayyavu Ramachandran, and Sunil Somashekara serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24233KA2016PTC086773
-
Company No.
086773
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Mar 2016
-
Date of AGM
27 Nov 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Aprus Bio-Medical Innovations?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anand Iyer
|
Director | 09-Mar-2016 | Current |
Ayyavu Ramachandran
|
Director | 09-Mar-2016 | Current |
|
Sunil Somashekara
|
Director | 31-Aug-2020 | Current |
Financial Performance of Aprus Bio-Medical Innovations.
Aprus Bio-Medical Innovations Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aprus Bio-Medical Innovations?
In 2017, Aprus Bio-Medical Innovations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Tuya Private LimitedAnand Iyer and Sunil Somashekara are mutual person
-
Aspis Coatings And Paints Private Limited
Anand Iyer and Sunil Somashekara are mutual person
-
Paraget Industrial Automation Technology Private Limited
Ayyavu Ramachandran is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aprus Bio-Medical Innovations?
Unlock and access historical data on people associated with Aprus Bio-Medical Innovations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aprus Bio-Medical Innovations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aprus Bio-Medical Innovations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.